Kimberly A. Kraynyak - Clinical Development, Inovio Pharmaceuticals

基本信息

Career Trajectory

Bio

No content for now

Research Interests

Papers共 70 篇Author StatisticsCo-AuthorSimilar Experts

By YearBy Citation主题筛选期刊级别筛选合作者筛选合作机构筛选

Safety and immunogenicity of INO-4800 DNA vaccine against SARS-CoV-2: a preliminary report of a randomized, blinded, placebo-controlled, Phase 2 clinical trial in adults at high risk of viral exposure

M. P. Mammen,P. Tebas,J. Agnes,M. Giffear,K. A. Kraynyak,E. Blackwood,D. Amante,E. L. Reuschel,M. Purwar,A. Christensen-Quick,N. Liu, V. M. Andrade, J. Carter, G. Garuffi, M. C. Diehl,A. Sylvester,M. P. Morrow,P. Pezzoli,A. J. Kulkarni,F. I. Zaidi,D. Frase,K. Liaw, H. Badie, K. O. Simon,T. R. F. Smith,S. Ramos, R. Spitz,J. Lee,M. Dallas,A. Shah Brown,J. E. Shea,J. J. Kim,D. B. Weiner,K. E. Broderick,J. D. Boyer,L. M. Humeau

medRxiv（2021）

Cited24Views0Bibtex

Phase 1 Study Of Safety, Tolerability And Immunogenicity Of The Human Telomerase (Htert)-Encoded Dna Plasmids Ino-1400 And Ino-1401 With Or Without Il-12 Dna Plasmid Ino-9012 In Adult Patients With Solid Tumors

Robert H Vonderheide,Kimberly A Kraynyak,Anthony F Shields,Autumn J McRee,Jennifer M Johnson, Weijing Sun,Ashish V Chintakuntlawar,Jan Pawlicki,Albert J Sylvester,Trevor McMullan,Robert Samuels,Joseph J Kim,David Weiner,Jean D Boyer,Matthew P Morrow,Laurent Humeau,Jeffrey M Skolnik

JOURNAL FOR IMMUNOTHERAPY OF CANCER（2021）

Cited15Views0WOSBibtex

571. Safety and Immunogenicity of INO-4800, a COVID-19 DNA Vaccine As a Primary Series and Booster

Open forum infectious diseasesno. Supplement_1 (2021): S387-S388

Cited1Views0Bibtex

Author Statistics

Co-Author

Co-Institution

D-Core

合作者
学生
导师

No result temporarily, you can search similar Scholar with the same research interest

Data Disclaimer

The page data are from open Internet sources, cooperative publishers and automatic analysis results through AI technology. We do not make any commitments and guarantees for the validity, accuracy, correctness, reliability, completeness and timeliness of the page data. If you have any questions, please contact us by email: report@aminer.cn